Evidence map›Paper›PMID 25963809›Full record

ArticleSynapse (New York, N.Y.)2015

Effect of low doses of methamphetamine on rat limbic-related neurotensin systems.

Mario E Alburges, Amanda J Hoonakker, Nathaniel M Cordova, Christina M Robson, Lisa M McFadden, Amber L Martin, Glen R Hanson

Abstract read
In one paragraph

Article in Synapse (New York, N.Y.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Mario E AlburgesDepartment of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah.
Amanda J HoonakkerDepartment of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah.
Nathaniel M CordovaDepartment of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah.
Christina M RobsonDepartment of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah.
Lisa M McFaddenDepartment of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah.
Amber L MartinDepartment of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah.
Glen R HansonSchool of Dentistry and Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah.
University of Utah · US

Funding

Vmat AND NEUROTOXICITYP01DA013367 · NIDA · UNIVERSITY OF UTAH · PI HANSON, GLEN R · 2001 to 2012
$10.1M
Role of Neurotensin Systems in Methamphetamine Self AdministrationR01DA031883 · NIDA · UNIVERSITY OF UTAH · PI HANSON, GLEN R · 2012 to 2016
$1.5M
Pharmacology and Toxicology of Methamphetamine Abuse (K05 DA00378)K05DA000378 · NIDA · UNIVERSITY OF UTAH · PI HANSON, GLEN R · 1998 to 2011
$1.2M
Serotonergic changes in the frontal cortex during methamphetamine reinstatementR00DA036012 · NIDA · UNIVERSITY OF SOUTH DAKOTA · PI MCFADDEN, LISA M · 2016 to 2018
$747k
Serotonergic changes in the frontal cortex during methamphetamine reinstatementK99DA036012 · NIDA · UNIVERSITY OF UTAH · PI MCFADDEN, LISA M · 2014 to 2015
$251k
NIDA NIH HHS DA000378NIDA NIH HHS DA013367NIDA NIH HHS DA031883NIDA NIH HHS DA036012NIDA NIH HHS K05 DA000378NIDA NIH HHS K99 DA036012NIDA NIH HHS P01 DA013367NIDA NIH HHS R00 DA036012NIDA NIH HHS R01 DA031883
6 · The paper itself

Abstract

Administration of methamphetamine (METH) alters limbic-related (LR) neurotensin (NT) systems. Thus, through a D1-receptor mechanism, noncontingent high doses (5-15 mg kg(-1)), and likely self-administration, of METH appears to reduce NT release causing its accumulation and an elevation of NT-like immunoreactivity (NTLI) in limbic-related NT pathways. For comparison, we tested the effect of low doses of METH, that are more like those used in therapy, on NTLI in the core and shell of the nucleus accumbens (NAc and NAs), prefrontal cortex (PFC), ventral tegmental area (VTA), the lateral habenula (Hb) and basolateral amygdala (Amyg). METH at the dose of 0.25 mg kg(-1) in particular, but not 1.00 mg kg(-1), decreased NTLI concentration in all of the LR structures studied, except for the prefrontal cortex; however, these effects were rapid and brief being observed at 5 h but not at 24 h after treatment. In all of the LR areas where NTLI levels were reduced after the low dose of METH, the effect was blocked by pretreatment with either a D1 or a D2 antagonist. Thus, opposite to high doses like those associated with abuse, the therapeutic-like low-dose METH treatment induced reduction in NT tissue levels likely reflected an increase in NT release and a short-term depletion of the levels of this neuropeptide in LR structures, manifesting features comparable to the response of basal ganglia NT systems to similar low doses of METH.

Indexed as

AnimalsBrainCentral Nervous System StimulantsDopamine AntagonistsDose-Response Relationship, DrugMaleMethamphetamineNeurotensinRadioimmunoassayRats, Sprague-DawleyReceptors, Dopamine D1Receptors, Dopamine D2Central Nervous System StimulantsDopamine AntagonistsMethamphetamineNeurotensinReceptors, Dopamine D1Receptors, Dopamine D2basal gangliadopamine antagonistsmethamphetamineneurotensinstimulant

Identifiers

PMID25963809
PMCPMC4481183
OpenAlexW2148923076

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.